<DOC>
	<DOC>NCT00976794</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of the combination of lithium and carbamazepine compared with lithium and valproate treating young bipolar patients.</brief_summary>
	<brief_title>Efficacy of Combined Treatment for Young Bipolar I Disorder</brief_title>
	<detailed_description>After the diagnostic assessments, the patients are allocated for one of the following groups of treatment: Group I: lithium + valproic acid Group II: lithium + carbamazepine Patients will be followed up for 8 weeks in phase I (acute treatment), 6 months in phase II (continuation treatment) and 12 months in phase III (maintenance treatment). Scales raters will be blind to the treatment. During phase II and III will continue only patients that achieve response, measured according to initial symptoms score in phase I.</detailed_description>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Clinical diagnosis of Bipolar Disorder, type I, in current episode (manic/hypomanic, mixed or depression) The patient or his (her) legal representative should understand the nature of the study and sign the Informed Consent. Schizophrenia or schizoaffective disorder Mental retardation Unstable clinical diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>BD I</keyword>
</DOC>